Condition: Neutropenia, Febrile · Sponsor: Universitaire Ziekenhuizen KU Leuven
The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection is found with the current "golden standard": long-term antibiotic treatment in adult hematology patients who develop neutropenic fever. The main question it aims to answer is: whether the short-term treatment is equally safe for patients, hence the name 'SAFE study'. Participants will be randomly assigned (randomized) to one of two treatment options once they develop neutropenic fever: short-term or long-term antibiotic treatment. An additional blood sample, urine sample and stool sample will be collected. Researchers will compare the short-term and the long-term antibiotic treatment groups to see if the short treatment is equally safe as the long-term treatment group.
This description comes directly from the study's public registry record.
Robina Aerts, MD · +32 16 34 48 77 · robina.aerts@kuleuven.be
Johan Maertens, MD, PhD · +32 16 34 66 70 · johan.maertens@uzleuven.be
Always discuss trial participation with your own doctor first.
| University Hospitals Leuven | Leuven, Vlaams-Brabant, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05926063